COVID-19 Vaccines For 2022

Authored by
Last reviewed
August 15, 2022

COVID-19 Vaccines For 2022

Innovative vaccine platforms such as DNA, mRNA, virus-like particles, viral vector, recombinant protein, live attenuated and inactivated virus approaches have developed COVID-19 vaccines.

On August 23, 2021, the U.S. Food and Drug Administration (FDA) Authorized the Pfizer-BioNTech mRNA Comirnaty vaccine and Approved the SpikeVax from Moderna, Inc. in 2022. And the Jcovden - Janssen COVID-19 vaccine is Authorized for use in the USA as of June 2022. On July 13, 2022, the FDA authorized Novavax's protein-based COVID-19 vaccine.

The U.S. CDC disclosed, 'Receipt of a primary series alone provides minimal protection against SARS-CoV-2 infection and transmission' on August 11, 2022.

The European Medicines Agency (EMA) had Authorized (6) COVID-19 vaccines as of August 2022. According to EMA recommendations on July 11, 2022, there is no clear evidence to support giving a second booster dose to people below 60 years of age who are not at higher risk of severe disease, and frequent COVID-19 booster shots could adversely affect the immune response. The decrease in immunity can be caused by several factors such as N1-methylpseudouridine, the spike protein, lipid nanoparticles, antibody-dependent enhancement, and the original antigenic stimulus. 

Furthermore, the WHO has Listed eleven COVID-19 vaccines. And GAVI recently reported over (120) COVID-19 vaccine candidates underwent clinical trials. On July 18, 2022, the European CDC released publications on COVID-19 vaccination strategies and a joint ECDC-WHO report on considerations for respiratory diseases as guidance for the second half of 2022.

COVID-19 Vaccine Research

August 11, 2022 - The WHO reported that during the Omicron dominant period in Israel, the estimated vaccine effectiveness (VE) of BNT162b2 against symptomatic COVID19 was 18% (95% CI, −2 to 34) at 14 to 27 days after the first dose and 48% (95% CI, 29 to 63) at 7 to 21 days after the second dose.

August 3, 2022 - The JAMA Network published a study that found during the Omicron wave in Iceland, two or more doses of vaccine were associated with a slightly higher probability of reinfection compared with 1 dose or less. 

July 19, 2022 - published: Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines. 'Our data suggest that although Omicron sublineages evade polyclonal neutralizing antibody responses elicited by primary vaccine series, vaccine boosters may provide sufficient protection against Omicron-induced severe disease.'

July 19, 2022 - The U.S. CDC's ACIP meeting reviewed data presented by Katherine E. Fleming-Dutra, MD COVID-19 Epidemiology Task Force: In May 2022, unvaccinated people ages ≥12 years had 9X higher COVID-19-associated death rates compared to those with a booster dose.

July 15, 2022 - A statistical analysis revealed that 42.1% of menstruating survey respondents reported a heavier menstrual flow after receiving an mRNA COVID-19 vaccine. Some experienced this in the first seven days, but many others saw changes 8-14 days after vaccination. Roughly the same proportion, 43.6%, reported no alteration of their menstrual flow after the vaccine, and a smaller percentage, 14.3%, saw a mix of no change or lighter flow, the researchers report. The analysis revealed that respondents who had experienced a pregnancy were most likely to report heavier bleeding after vaccination, with a slight increase among those who had not given birth. 

July 11, 2022 - A Kaiser Permanente–led study revealed that both mRNA COVID vaccines are associated with an increased risk of myocarditis and pericarditis. "These results indicate that both mRNA vaccines were associated with a markedly elevated risk of myocarditis and pericarditis in 18–39-year-olds and that the risk during the seven days after vaccination was modestly greater after mRNA-1273 than after BNT162b2," the authors concluded.

July 7, 2022 - The NEJM published an Original Article that found no discernable differences in protection against symptomatic BA.1 and BA.2 infection were seen with previous infection, vaccination, and hybrid immunity. Vaccination enhanced protection among persons who had had a previous infection. Hybrid immunity resulting from previous infection and recent booster vaccination conferred the strongest protection.

April 28, 2022 - The NEJM published an EDITORIAL by Paul A. Offit, M.D.:Covid-19 Boosters — Where from Here?

COVID-19 Vaccine and Heart Health Risk

U.S. CDC researchers highlighted the mRNA vaccine-heart inflammation link on June 29, 2021, in an Editorial published in the Journal of the American Medical Association Cardiology, citing the journal's new published studies from Duke University Medical Center and the U.S. Military Health System and earlier AAPediatrics study (June 1, 2021) led by Oregon Health and Science University researchers.

Additional vaccine news is published at